MedPath

Clinical Utility of Whole Breast Screening Ultrasound in Patients Undergoing Digital Breast Tomosynthesis

Completed
Conditions
Breast Screening
Interventions
Procedure: breast ultrasound
Procedure: DBT (Full field digital mammography + tomosynthesis)
Registration Number
NCT02174406
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Brief Summary

The purpose of this study is to determine whether ultrasound or Digital breast tomosynthesis (DBT) detects more cancers and to compare the types of cancers detected on ultrasound and DBT.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
1494
Inclusion Criteria
  • Any women scheduled for screening WBUS and a screening FFDM on the same day or within the following 30 days of each other.
Read More
Exclusion Criteria
  • Age < 30 years old
  • Male patients
  • Patients with any clinical symptoms (palpable mass, nipple discharge, etc)
  • Patients with known cancer
  • Patients with any breast surgery or biopsy within 90 days prior to the study
  • Patients with breast implants
  • Patients pregnant or lactating
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
women scheduled for breast screeningbreast ultrasoundEach patient will have the following: * Screening whole breast ultrasound * DBT (Full field digital mammography + tomosynthesis views in the CC and MLO projections). The only change in patient management will be the addition of digital breast tomosynthesis views in patients scheduled for FFDM alone. DBT is currently clinically approved and being offered on a voluntary basis to patients scheduled for FFDM.
women scheduled for breast screeningDBT (Full field digital mammography + tomosynthesis)Each patient will have the following: * Screening whole breast ultrasound * DBT (Full field digital mammography + tomosynthesis views in the CC and MLO projections). The only change in patient management will be the addition of digital breast tomosynthesis views in patients scheduled for FFDM alone. DBT is currently clinically approved and being offered on a voluntary basis to patients scheduled for FFDM.
Primary Outcome Measures
NameTimeMethod
estimate the cancer detection rates2 years

The detection rate of each imaging test is defined as the proportion of patients who are positive on that imaging test who truly have the disease compared to the total number of women screened. A positive imaging test is defined as a test with a recommendation for biopsy (BI-RADS 4 or 5).

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Memorial Sloan Kettering Cancer Center

🇺🇸

New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath